Trump Media Plans To Launch Prediction Markets Offering On Truth Social

Published : Oct 28, 2025, 07:20 PM IST
https://stocktwits.com/news-articles/markets/equity/trump-media-truth-social-prediction-markets-truth-predict-djt-stock-soars/cLGj0GfR3HN

Synopsis

Trump Media & Technology Group Corp. (DJT) on Tuesday announced plans to launch a prediction markets offering on its social media platform, Truth Social.

Trump Media stated that it is partnering with Crypto.com | Derivatives North America (CDNA) to offer the prediction markets feature on Truth Social. CDNA is a Commodity Futures Trading Commission (CFTC) registered exchange and clearing house.

Trump Media shares were up more than 6% in Tuesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory at the time of writing.

The feature, called Truth Predict, will allow users to trade prediction contracts on major events, such as elections, changes in interest and inflation rates, gold and crude oil prices, and major sporting events, the company said in its announcement.

“Following the integration, Truth Social will be the first social media platform to offer its users technology to access embedded prediction markets capabilities through CDNA,” the company stated in its announcement.

Get updates to this story developing directly on Stocktwits.<

For updates and corrections, email newsroom[at]stocktwits[dot]com.<

PREV

Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.

Recommended Stories

Why Did ROLR Stock Close More Than 400% Higher Today?
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly